---

COMPREHENSIVE POSTGRADUATE THEORY EXAMINATION NOTES

PLATELET RICH FIBRIN (PRF), PLATELET RICH PLASMA (PRP), AND RECENT ADVANCES

---

SECTION I: PLATELET RICH PLASMA (PRP)

---

1. INTRODUCTION AND DEFINITION

• Platelet Rich Plasma (PRP) is defined as "an autologous concentrate of human platelets in plasma." (Essentials of Clinical Periodontology and Periodontics, 5th ed. — Shantipriya Reddy; hereafter "Essentials")
• PRP is described as "an otherwise normal autogenous blood clot that contains a highly concentrated number of platelets. Because it is the patient's own blood, it is free of transmissible diseases and cannot cause hypersensitivity reactions." (Dental and Craniofacial Applications of Platelet-Rich Plasma — Marx & Garg, 2005; hereafter "Marx & Garg")
• PRP is "an autologous source of platelet-derived growth factors and transforming growth factors that is obtained by sequestering and concentrating platelets by centrifugation." (Carranza's Clinical Periodontology, 10th ed.; hereafter "Carranza 10th")
• PRP was conceptualized "in the 1970s in the field of hematology to treat thrombocytopenia." (Aesthetic Clinician's Guide to Platelet Rich Plasma — Khetarpal, Springer 2021; hereafter "Khetarpal")

---

2. HISTORY AND DEVELOPMENT OF PRP

• The use of blood platelets was first explored in 1954 for its effect on blood fluidity. (Platelet Rich Fibrin Preparation Techniques — Cezar Edward Lahham, 2022; hereafter "Lahham")
• PRP entered the field of dentistry and oral surgery in 1997 through the work of Whitman et al. (Lahham; Essentials)
• PRP was "developed by Whitman et al. (1974) for oral surgical procedures." (Essentials)
• Marx (1998) published the seminal study in Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics that documented PRP is a concentration of platelets 4 to 7 times above baseline peripheral blood platelet levels. (Marx & Garg)
• PRP has been widely used in "dermatology, orthopedics, maxillofacial surgery, cardiac surgery, pediatric surgery, urogynecology, plastic surgery, and ophthalmology." (Khetarpal)
• "Today, PRP is a multimillion-dollar industry with a projected growth estimated between 380 million and 4.5 billion over the course of 5-10 years as of 2018." (Khetarpal)

---

3. PLATELET BIOLOGY AND MECHANISM OF ACTION

3.1 The Platelet

• Platelets are "the responsible component for the activation and release of crucial growth factors including platelet-derived growth factor (PDGF), coagulation factors, adhesion molecules, cytokines, and angiogenic factors, which enables the recruitment and activity of fibroblasts, leukocytes, macrophages, and mesenchymal stem cells (MSCs)." (Platelet Rich Fibrin in Regenerative Dentistry — Miron & Choukroun, 2017; hereafter "Miron & Choukroun")
• Platelet concentrate "works via the degranulation of the α granules in platelets, which contain the synthesized and prepacked growth factors." (Essentials)

Flowchart: Mechanism of Action of Platelet Concentrates (Essentials — Flowchart 54.1)

Blood drawn from patient
        |
        v
Centrifugation → Separation into layers
        |
        v
Platelet concentrate obtained
        |
        v
Activation of platelets (degranulation of α granules)
        |
        v
Release of growth factors (PDGF, TGF-β, VEGF, EGF, IGF, IL-1, bFGF, PAF-4)
        |
        v
Growth factors bind to membrane receptors on target cells
        |
        v
Signal transduction proteins migrate to nucleus
        |
        v
Expression of normal genes → Cell proliferation, migration, differentiation
        |
        v
Tissue repair, angiogenesis, matrix synthesis, regeneration

---

4. GROWTH FACTORS IN PLATELETS

---

5. WHAT IS PRP? — DEFINITION AND MINIMUM THRESHOLD

• "The minimum platelet count required for a blood clot to qualify as PRP may be arguable, but a concentration of about 1 million platelets/µL, or about 4 to 7 times the usual baseline platelet [count]" is required. (Marx & Garg)
• The seminal study confirmed PRP is "a concentration of platelets 4 to 7 times above baseline peripheral blood platelet levels." (Marx & Garg)
• "Both the SmartPReP and the PCCS... yielded over 1 million platelets/µL in a standard volume of 60 mL, which is the clinical benchmark for wound healing enhancement." (Marx & Garg)

Cell Composition: Normal Blood Clot vs PRP (Marx & Garg)

---

6. TECHNIQUE FOR PRP PREPARATION

Step-by-Step Protocol (Essentials — Flowchart 54.1)

Withdraw 10-20 mL of venous blood
         |
         v
Add anticoagulant: Citrate-Phosphate-Dextrose (CPD)
   [ACD-A = Anticoagulant Citrate Dextrose-A — preferred over EDTA]
         |
         v
FIRST CENTRIFUGATION — "Soft Spin"
(Lower speed, shorter time)
         |
         v
Blood separates into 3 layers:
  TOP: Acellular plasma — 40% PPP (Platelet Poor Plasma)
  MIDDLE: Buffy coat — 5% PRP (Concentrated platelets)
  BOTTOM: Red Blood Cells — 55%
         |
         v
Aspirate PPP, PRP, and some RBCs (sterile syringe)
Transfer to second tube
         |
         v
SECOND CENTRIFUGATION — "Hard Spin"
(Longer and faster than first spin)
         |
         v
Platelets concentrated at bottom of tube = PRP
         |
         v
Mix with Bovine Thrombin + Calcium Chloride at time of application
         |
         v
Gel-like platelet concentrate formed for clinical use

Important Technical Details (Marx & Garg)

• A 19-gauge needle or larger should be used to avoid platelet disruption or activation in the lumen of a narrow needle.
• Preferred phlebotomy site: antecubital vein or cephalic vein over the radius.
• ACD-A (Anticoagulant Citrate Dextrose A) is recommended; EDTA is NOT recommended.
• Blood volume required: usually 20 to 60 mL.
• Bovine thrombin (5 mL of 10% CaCl₂ solution added to lyophilized bovine thrombin): "leads to rapid clotting within 6 to 10 seconds" — standard for activating PRP.
• PRP has a pH of 6.5 to 6.7 (mature blood clot pH = 7.0–7.2).

---

7. CLINICAL EFFECTS OF PRP

7.1 Effects on Bone Regeneration (Marx & Garg)

• "Bone graft cells do indeed possess membrane receptors for nearly all of the growth factors contained within platelets."
• Radiographs and CT scans showed "increase in bone mineral density in PRP-supported grafts that ranged from 1.6 to 2.2 times that of non-PRP-supported grafts."
• Histomorphometry: Autogenous bone graft without PRP: trabecular bone value 55% ± 8%; PRP-enhanced grafts: 74% ± 11% — "increased density of bone produced by PRP as well as an advanced rate of maturity."

• Meta-analysis (Del Fabbro et al. 2011, 10 studies): "significantly greater CAL gain in cases treated with PRP compared to control sites (mean adjusted percentage difference 5.50%; 95% CI 1.32–9.67%; P=0.01). The mean weighted CAL gain difference was 0.50 mm." (Clinical Periodontology and Implant Dentistry 6th ed. — Lang & Lindhe; hereafter "Lang & Lindhe")

7.2 Effects on Osseointegration (Marx & Garg)

• "Osseointegration of dental implants arises from cell migration, differentiation, bone formation, and bone remodeling along the implant surface; each of these processes is platelet- and blood clot-dependent."
• PRP enhances osseointegration especially in: elderly, individuals with osteoporosis, diabetes, other forms of compromised bone regeneration, and the posterior maxilla.
• PRP coats the implant surface and microgap (about 25 µm wide) between actual bone and metal surface.

7.3 Effects on Soft Tissue Healing (Marx & Garg)

• PRP enhances: mucosal flaps, gingival grafts, palatal donor sites, skin graft recipient sites, dermal fat grafts, and facial wounds.

---

8. CLINICAL APPLICATIONS OF PRP (Marx & Garg; Essentials)

---

9. PRP DEVICES AND SELECTION CRITERIA (Marx & Garg)

• "Key features that characterize effective PRP machines":
  1. Must yield over 1 million platelets/µL (clinical benchmark)
  2. Platelet recovery >55%
  3. Minimal operator time (less than 10 minutes preferred)
  4. Minimal processing steps to reduce contamination risk
  5. Single or double-spin device
  6. Low coefficient of variance for reproducibility
  7. Good platelet viability and activity
• SmartPReP and PCCS were "significantly superior in platelet concentration and platelet yield." Both yielded over 1 million platelets/µL from 60 mL blood; platelet recovery >55%.
• SmartPReP and CATS showed consistent results with "coefficients of variance which were a low 13% and 16% respectively."
• The Access device showed low viability (due to "mechanical disruption or heat exposure during processing") — should be avoided.

---

10. DOES PRP PROMOTE INFECTIONS? (Marx & Garg)

• "PRP has a pH of 6.5 to 6.7, whereas a mature blood clot has a pH of 7.0 to 7.2 and therefore may even inhibit bacterial growth, as do other acidic solutions."
• "Based on our experience... no differences in the promotion or inhibition of infection complications have been found; each has an incidence of 2.0% to 3.5%."
• However: "preparation of PRP requires the use of an aseptic technique."

---

---

SECTION II: PLATELET RICH FIBRIN (PRF)

---

1. DEFINITION AND INTRODUCTION

• PRF is a second-generation platelet concentrate described by Choukroun et al. (Essentials; Miron & Choukroun)
• "Autologous PRF has therefore been introduced and utilized as an extremely physiological, safe, and reliable biomaterial for wound healing in the body since it is derived from 100% natural human blood." (Miron & Choukroun)
• PRF functions as: (1) a growth factor reserve and delivery system, (2) a biocompatible scaffold, and (3) a reservoir for living autologous cells capable of contributing to wound healing. (Miron & Choukroun)
• "Unlike PRP, it does not require the addition of an anticoagulant." (Essentials)

---

2. HISTORY OF PRF

• PRF was "first introduced by Choukroun" and first published in: Choukroun J, Adda F, Schoeffler C, Vervelle A. "Une opportunité en paro-implantologie: le PRF." Implantodontie. 2001;42(55):e62. (Miron & Choukroun)
• It originated at "the Pain Clinic in Nice, France" in the early 2000s. (Miron & Choukroun)
• "After introduction of PRF in 2001 and its modification (A-PRF+ and i-PRF), the clinical application of PRF penetrated many surgical fields." (Miron & Choukroun)
• "It has now been over 15 years since the first use of PRF." (Miron & Choukroun — Foreword)
• "Nowadays, over 500 scientific articles evaluating its use in vitro, in vivo, and clinically have documented its regenerative potential." (Miron & Choukroun)

---

3. CLASSIFICATION OF PLATELET CONCENTRATES

Three Generations (Essentials; Miron & Choukroun)

Dohan Ehrenfest Classification of Platelet Concentrates (Miron & Choukroun)

---

4. THREE PRIMARY ADVANTAGES OF PRF OVER PRP (Miron & Choukroun)

4.1 Leukocyte Content

• PRF contains a higher number of leukocytes compared to PRP and PRGF.
• "The initially developed PRF (also termed L-PRF) concentrates contain 97% platelets and more than 50% leukocytes within a high-density fibrin network when compared to whole blood."
• "The amount of white blood cells in PRF has been determined at around 50% (with variability depending on the human)."
• Leukocytes include: monocytes, macrophages, lymphocytes, neutrophils (granulocytes).
• "Extraction of third molars have specifically shown up to a 10-fold decrease in osteomyelitis infections as well as greater wound healing following simple placement of PRF into extraction sockets." (Miron & Choukroun)

4.2 Natural Fibrin Matrix

• "The lack of anti-coagulants results in a fibrin matrix. Naturally without anti-coagulants blood will clot and for these reasons, centrifugation must take place immediately following blood collection."
• "What was once thought to be simply a carrier for growth factors and cells, the fibrin matrix has since been shown to be a main feature of PRF."

4.3 Cytokines (Growth Factors) in PRF

• PRF contains: TGF-β (rapid proliferation of various cell types), PDGF (migration, proliferation, survival of mesenchymal cells), VEGF (angiogenesis), EGF and IGF (proliferation and differentiation of many cell types). (Miron & Choukroun)

---

5. TECHNIQUE FOR PRF PREPARATION

Protocol (Essentials; Miron & Choukroun; Lahham)

Venous blood withdrawal (10 mL — no anticoagulant added)
              |
              v
IMMEDIATELY place in glass/glass-coated plastic tube
(Must be placed in centrifuge immediately — blood will clot)
              |
              v
Centrifugation: 2700 rpm for 12 minutes (750g)
[Essentials states: 3000 rpm for 10 minutes]
              |
              v
Three layers form in tube after centrifugation:
  TOP layer:    Platelet-Poor Plasma (PPP) — acellular
  MIDDLE layer: PRF CLOT (fibrin gel — the harvested product)
  BOTTOM layer: Red Blood Cells
              |
              v
Extract only the middle viscous/gel layer (L-PRF clots)
Cut off red portions
              |
              v
OPTION A — PRF CLOT: Use directly
OPTION B — PRF MEMBRANE: Place between two sterile gauze/glass plates
and compress for 4-5 minutes → L-PRF membrane formed
              |
              v
Clinical application

Centrifugation Parameters from References

Parts of PRF After Centrifugation (Essentials — Fig. 54.8)

┌──────────────────────────────┐
│  TOP: PPP (Platelet-Poor Plasma) — Acellular         │
├──────────────────────────────┤
│  MIDDLE: PRF CLOT (Platelet-Rich Fibrin)              │
│   [97% platelets, >50% leukocytes in fibrin network] │
├──────────────────────────────┤
│  BOTTOM: Red Blood Cells                              │
└──────────────────────────────┘

---

6. CELLULAR COMPONENTS OF PRF (Miron & Choukroun)

• PRF is "a concentrate of white blood cells, platelets, and fibrin."
• Four components of blood: plasma, red blood cells, white blood cells, and platelets.
• Leukocyte types trapped in PRF fibrin network: monocytes, macrophages, lymphocytes (PRF is notable for introducing lymphocytes at day 0, which typically appear only at 7 days in normal wound healing), neutrophilic granulocytes.
• "Whereas lymphocytes typically arise at 7 days, the ability for PRF to introduce a high number at day 0 acts to speed the regenerative phase during this process." (Miron & Choukroun)

---

7. ADVANTAGES OF THE FIBRIN NETWORK IN PRF

Three-Dimensional Fibrin Network (Miron & Choukroun)

1. Provides a scaffold for cell migration and proliferation.
2. Acts as a carrier for growth factors — enables sustained, slow release (as opposed to PRP's rapid "burst" release).
3. Contains cell adhesion molecules: fibrin, fibronectin, and vitronectin that coat implant surfaces and bridge microgaps.
4. Supports angiogenesis — new blood vessel formation.
5. "A-PRF and A-PRF+ samples were able to locally demonstrate up to a 300% significant increase in collagen1 synthesis."

---

8. PRF vs PRP — KEY DIFFERENCES

---

9. THE LOW-SPEED CENTRIFUGATION CONCEPT (LSCC) — RECENT ADVANCE

LSCC Definition (Miron & Choukroun — Chapter 3, Choukroun & Ghanaati)

• "The Low-Speed Centrifugation Concept (LSCC) indicates that, by reducing the relevant centrifugation force (RCF), the regeneration capacity of PRF matrices can be improved."
• "The trend in dentistry has gradually shifted toward more bioactive materials including cell-based therapies."

Development of Advanced PRF Matrices Following LSCC

Growth Factor Release Comparison (Miron & Choukroun — Fujioka-Kobayashi et al. 2017)

A-PRF+ >> A-PRF >> L-PRF >> PRP
(Highest)                   (Lowest sustained release)

• PRP shows a rapid initial burst of growth factors at 15 min–60 min, then falls.
• A-PRF+ shows the highest accumulated release over 10 days for TGF-β1, PDGF, VEGF.
• "The initial burst of growth factor increase from PRP; however, after a 10-day period, significantly higher growth factors are released from A-PRF." (Kobayashi et al. 2016)

Cell Comparison (Flow Cytometry) (Miron & Choukroun)

• "The total platelet number significantly increased from PRF to A-PRF and A-PRF+."
• "The total leukocyte number was only significantly higher when comparing A-PRF+ to PRF."

---

10. INJECTABLE PRF (i-PRF) (Miron & Choukroun)

• Injectable PRF is "formulated utilizing lower centrifugation forces for shorter time periods."
• "PRF variants are mostly solid or dense gels and cannot be injected although recently the development of an injectable liquid-PRF" was achieved.
• i-PRF vs PRP comparison: "Both formulations exhibited high biocompatibility of human gingival fibroblasts as well as significantly induced higher cell migration when compared to control tissue-culture plastic in vitro."
• i-PRF showed significantly highest mRNA levels of TGF-β at 7 days, PDGF at 3 days, and collagen1 expression at both 3 and 7 days — compared to PRP.
• "i-PRF induced significantly higher migration, whereas PRP demonstrated significantly highest cellular proliferation."
• i-PRF is "now utilized in the field of facial aesthetics in a similar manner to PRP."

---

11. CLINICAL APPLICATIONS OF PRF IN PERIODONTOLOGY AND DENTISTRY

---

12. EFFECT OF PRF ON PERIOSTEUM BEHAVIOR (Miron & Choukroun)

• "Following years of practice with the use of PRF, one biological property observed with almost every surgical technique" was an enhanced effect on periosteum.
• PRF acts to maintain periosteum vitality and accelerate primary closure.

---

13. ADVANTAGES AND LIMITATIONS OF PRF

Advantages of PRF over PRP (Essentials — Shantipriya Reddy)

1. No addition of anticoagulant to blood — hence free from associated risks.
2. Contains large quantity of platelet and leukocyte cytokines.
3. More efficient cell migration, proliferation and hemostasis.
4. PRF can be obtained in a definite firm structure (predictable handling).
5. Simplified, single-spin preparation.
6. Shorter preparation time.

Advantages of PRP (Essentials)

1. Safe autogenous preparation.
2. Simplified and cost-effective process.
3. Convenient for patient since blood is collected in the immediate preoperative period.
4. Accelerated healing due to presence of growth factors at the surgical site.

Limitations of PRF Technology (Essentials)

1. "Only a limited volume of PRF can be used, since it is obtained from an autologous blood sample."
2. "Platelet-rich fibrin tissue banks are unfeasible."

---

14. CELL BEHAVIOR IN RESPONSE TO PRF VARIANTS (Miron & Choukroun — Fujioka-Kobayashi et al. 2017)

Cell Behavior: L-PRF vs A-PRF vs A-PRF+

• "Gingival fibroblasts cultured with A-PRF+ demonstrated significantly higher mRNA levels of TGF-β, PDGF, and collagen1 at either 3 or 7 days."
• "A-PRF and A-PRF+ samples were able to locally demonstrate up to a 300% significant increase in collagen1 synthesis."
• "Cellular migration and proliferation rate in A-PRF and A-PRF+ were significantly higher than those in PRF (L-PRF)."

Cell Behavior: PRP vs i-PRF

• "i-PRF induced significantly higher migration, whereas PRP demonstrated significantly highest cellular proliferation."
• "i-PRF showed significantly highest mRNA levels of TGF-β at 7 days, PDGF at 3 days, and collagen1 expression at both 3 and 7 days."

---

---

SECTION III: RECENT ADVANCES

---

1. RECENT TERMINOLOGY CHANGES (Miron & Choukroun)

---

2. RECENT ADVANCES — OVERVIEW (Miron & Choukroun; Khetarpal)

A. Low-Speed Centrifugation Concept (LSCC)

• Introduced by Choukroun and Ghanaati.
• Key principle: reducing RCF results in more platelets and leukocytes retained in the PRF matrix, and prolonged growth factor release.
• "By reducing the relevant centrifugation force (RCF), the regeneration capacity of PRF matrices can be improved."

B. A-PRF and A-PRF+ Development

• Developed following LSCC.
• A-PRF+ has "improved growth factor release pattern" especially VEGF.
• "A-PRF+ demonstrated significantly highest accumulated growth factors, especially VEGF, compared to PRF and A-PRF."
• "By means of the LSCC, advanced PRF matrices exhibit an improved regeneration capacity with direct impact on cellular function and growth factor release."

C. Injectable PRF (i-PRF)

• First development of a liquid, injectable form of PRF.
• Enables application in soft tissue procedures including gingival recession treatment.
• The "Simonpieri technique" uses i-PRF for "adequate graft stability and compaction" in immediate full-arch loading.
• i-PRF is also "now utilized in the field of facial aesthetics in a similar manner to PRP."

D. Centrifuge Comparison with Other Platelet Concentrates (Miron & Choukroun — Fig. 3.4)

E. PRF in Combination Therapies — Recent Advances (Miron & Choukroun)

• PRF combined with bone substitutes to accelerate/enhance regeneration.
• PRF combined with GBR membranes — PRF as both scaffold and growth factor source.
• "Combination with biomaterials is a promising approach in guided bone and tissue regeneration to enhance the capacity of the applied biomaterials and to enhance their bioactivity."
• PRF as "biocatalyst" in impaired healing regions (e.g., BRONJ/MRONJ, diabetic wounds).
• T-PRF (titanium-prepared PRF) and CGF (Concentrated Growth Factors) — newer systems.

F. PRF in Facial Aesthetics (Miron & Choukroun; Regenerative Medicine in Aesthetic Treatments — Aamer Khan, CRC Press 2022)

• "Induction of dermal collagenesis, angiogenesis, and adipogenesis in human skin by injection of platelet-rich fibrin matrix." (Sclafani & McCormick, 2012)
• "PRF matrix in wound healing: a randomized controlled clinical trial." (Chignon-Sicard et al. 2012)
• i-PRF/PRF used for: facial tissue regeneration, scar repair, hair loss, skin rejuvenation.
• "Concentrated growth factors can be used to stimulate tissue repair. These factors are present in platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and treatments that use recombinant factors. They work by switching the function of ageing tissues from 'stop' mode to a 'go' position." (Aamer Khan — Regenerative Medicine in Aesthetic Treatments)

G. PRP in Dermatology — Recent Advances (Khetarpal — Aesthetic Clinician's Guide to PRP)

• PRP has been shown to "increase both hair count and density for androgenic alopecia (AGA) and alopecia areata (AA)."
• "In combination with PRP treatments, it has been shown that there is an average of 15.1% increased follicular unit density (FUD)." (Uebel et al. 2006)
• Average of 735,000 surgical hair restoration procedures for over 1.4 million non-surgical patients in 2019 alone.
• PRP for alopecia: commercially available ready-to-use PRP kits range from $175 to $1150 per kit.
• Quality of life improvement: Hairdex score improved (25.0 before vs 19.3 after PRP; p=0.02) — "most pronounced improvement in emotions and self-confidence."

H. PRF in Orthopedic Medicine (Miron & Choukroun)

• "injectable PRF into osteoarthritic knees as a second-generation platelet concentrate without use of anti-coagulants."
• "Rotator cuff repair: a prospective, randomized, double-blinded study." (Weber et al. 2013)

---

15. COMPARISON TABLE: DIFFERENT REFERENCES' VIEWPOINTS

---

16. FOUR PHASES OF WOUND HEALING AND PRF (Miron & Choukroun)

Phase 1: HEMOSTASIS
    |── Platelet aggregation; fibrin clot; PRF introduced at Day 0
    |
Phase 2: INFLAMMATION (Days 0-5)
    |── Neutrophils; macrophages; PRF leukocytes accelerate
    |
Phase 3: PROLIFERATION (Days 5-21)
    |── Fibroblasts; angiogenesis; collagen synthesis
    |── PRF growth factors (TGF-β, PDGF, VEGF) sustain phase
    |── PRF introduces LYMPHOCYTES at Day 0 (normally arrive Day 7)
    |
Phase 4: MATURATION / REMODELING (Days 21 — months)
    |── Collagen reorganization; scar formation
    |── PRF 3D fibrin scaffold guides organized collagen formation

---

17. GROWTH FACTOR TABLE FOR PRF — INDIVIDUAL ROLES (Miron & Choukroun)

---

18. BONE EFFECTS OF PRP — CLINICALLY IMPORTANT DATA (Marx & Garg)

• PRP on autogenous bone grafts: radiographic bone mineral density 1.6 to 2.2 times greater than non-PRP grafts.
• Histomorphometry at 4 months: PRP-enhanced graft = 74% ± 11% trabecular bone vs. non-PRP = 55% ± 8% vs. native mandible = 38% ± 6%.
• "This measure indicated an increased density of bone produced by the PRP as well as an advanced rate of maturity."

---

19. IMPORTANT EXAMINER KEYWORDS (Summary)

---

20. MCQ ANSWERS FROM ESSENTIALS (Shantipriya Reddy, 5th ed.)

• Q: PRF belongs to which generation? → 2nd generation platelet concentrate (answer: b)
• Q: For PRF preparation, centrifugation is: → 3,000 rpm for 10 minutes (answer: a)
• Q: PRF was first introduced by: → Choukroun (answer: c)
• Q: About PRF — all true EXCEPT: → Bottom layer consists of concentrated platelets presenting as a buffy coat (this is a feature of PRP, NOT PRF — in PRF the bottom layer is red blood cells) (answer: c)

---

SOURCES / REFERENCES CITED

1. Miron RJ, Choukroun J (Eds.). Platelet Rich Fibrin in Regenerative Dentistry: Biological Background and Clinical Indications. John Wiley & Sons Ltd, 2017. (Primary reference for PRF biology, LSCC, A-PRF, i-PRF, growth factor release)
2. Marx RE, Garg AK. Dental and Craniofacial Applications of Platelet-Rich Plasma. Quintessence Publishing, 2005. (Primary reference for PRP biology, growth factors, clinical applications, bone regeneration data)
3. Reddy S. Essentials of Clinical Periodontology and Periodontics, 5th Edition. Jaypee Brothers, 2017/2018. (Classification of platelet concentrates, technique, clinical applications)
4. Khetarpal S (Ed.). Aesthetic Clinician's Guide to Platelet Rich Plasma. Springer, 2021. (History, PRP in dermatology/alopecia, basic science)
5. Khan A. Regenerative Medicine in Aesthetic Treatments: Stem Cells, Stromal Vascular Fraction, Platelet Rich Plasma, and Platelet Rich Fibrin. CRC Press, 2022. (PRP/PRF in aesthetics, growth factors)
6. Newman MG, Takei HH, Klokkevold PR, Carranza FA (Eds.). Newman and Carranza's Clinical Periodontology and Implantology, 14th Edition. Elsevier. (PRF/PRP in periodontal context)
7. Newman MG, Takei HH, Klokkevold PR, Carranza FA (Eds.). Carranza's Clinical Periodontology, 10th Edition. Saunders/Elsevier, 2006. (Autologous platelet concentration; PRP in bone augmentation)
8. Lang NP, Lindhe J (Eds.). Clinical Periodontology and Implant Dentistry, 6th Edition. Wiley-Blackwell, 2015. (PRP meta-analysis data; CAL gain; PRP + bone graft combinations)
9. Lahham CE. Platelet-Rich Fibrin Preparation Techniques, 2022. (PRF preparation protocol; L-PRF membrane technique)
10. Dental & Craniofacial Applications of PRP (second Marx & Garg file). (Overlapping content with primary Marx & Garg reference)

---

EXAMINER'S GUIDE TO THIS ANSWER